2020年度業績

【英文論文】
Tashiro T, Imamura K, Tomita Y, Tamanoi D, Takaki A, Sugahara K, Sato R, Saruwatari K, Sakata S, Inaba M, Ushijima S, Hirata N, Sakagami T. Heterogeneous tumor-immune microenvironments between primary and metastatic tumors in a patient with ALK rearrangement-positive large cell neuroendocrine carcinoma.
Int J Mol Sci. 2021 Feb 11;25(1):59.

Sakata S, Imamura K, Tajima Y, Masuda Y, Sato R, Yoshida C, Okamoto S, Saeki S, Tomita Y, Sakagami T. Heterogeneous tumor-immune microenvironments between primary and metastatic carcinoid tumors differentially respond to anti-PD-L1 antibody therapy.
Thoracic Cancer. 2021;2(3):397-401.

Lee MJ, Tomita Y, Yuno A, Lee S, Abrouk NE, Oronsky B, Caroen S and Trepel JB. Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinomareintroduced platinum-based chemotherapy in relapsed small cell carcinoma.
Expert Opin Investig Drugs. 2021;30(2):177-183.

Migiyama Y, Sakata S, Iyama S, Tokunaga K, Saruwatari K Tomita Y,, Saeki S, Okamoto S, Ichiyasu H, Sakagami T. Airway Psoudomonas aeruginosa density in mechanically ventilated patients: clinical impact and relation to therapeutic efficacy of antibiotics.
Crit Care. 2021 Feb 11;25(1):59.

Apolo AB, Nadal R, Tomita Y, Davarpanah NN, Cordes LM, Steinberg SM, Cao L, Parnes HL, Costello R, Merino MJ, Folio LR, Lindenberg L, Raffeld M, Lin J, Lee MJ, Lee S, Alarcon SV, Yuno A, Dawson NA, Allette K, Roy A, De Silva D, Lee MM, Sissung TM, Figg WD, Agarwal PK, Wright JJ, Ning YM, Gulley JL, Dahut WL, Bottaro DP, Trepel JB. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncol. 2020;21(8):1099-1109.

Madan RA, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee MJ, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL. Cabozantinib plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer. BJU International. 2020 Sep 24. doi: 10.1111/bju.15227.

Tomita Y, Ikeda T, Sakata S, Saruwatari K, Sato R, Iyama S, Jodai T, Akaike K, Ishizuka S, Saeki S, Sakagami T. Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer.
Cancer Immunol Res. 2020; 8(19):1236-1242.

Tomita Y, Oronsky B, Abrouk N, Cabrales P, Reid TR, Lee MJ, Yuno A, Baker J, Lee S, Trepel JB. In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit.
Transl Lung Cancer Res. 2021;10(1):274-278.

Tomita Y, Ikeda T, Sato R, Sakagami T. Association between HLA gene polymorphisms and mortality of COVID-19: An in silico analysis.
Immunity, Inflammation and Disease. 2020;8(4):684-694.

Tomita Y, Sato R, Ikeda T, Sakagami T. BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis.
Vaccine. 2020;38:6352-6356.

Akaike K, Saruwatari K, Oda S, Shiraishi S, Takahashi H, Hamada S, Iyama S, Horio Y, Tomita Y, Saeki S, Okamoto S, Ichiyasu H, Fujii K, Sakagami T. Predictive value of 18F-FDG PET/CT for acute exacerbation of interstitial lung disease in patients with lung cancer and interstitial lung disease treated with chemotherapy.
Int J Clin Oncol. 2020;25(4):681-690.

Kuriyama H, Fukushima S, Nakahara S, Kanemaru H, Miyashita A, Aoi A, Tomita Y, Kawasaki T, Nosaka K, Ihn H. Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma.
J Dermatol. 2020 Jun;47(6):e235-e237.

Tashiro T, Tomita Y, Inaba M, Hayashi K, Hirata N, Sakagami T. Severe pulmonary alveolar proteinosis with respiratory failure treated by intrapulmonary percussive ventilation.
Respirol Case Rep. 2020 Nov 4;8(9):e00676.

Anai M, Akaike K, Iwagoe H, Akasaka T, Higuchi T, Miyazaki A, Naito D, Tajima Y, Takahashi H, Komatsu T, Masunaga A, Kishi H, Fujii K, Fukuda K, Tomita Y, Saeki S, Ichiyasu H, Sakagami T. Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia.
Respir Investig. 2021 Mar;59(2):187-193.

Hamada S, Ichiyasu H, Inaba M, Takahashi H, Sadamatsu T, Akaike K, Masunaga A, Tashiro Y, Hirata N, Yoshinaga T, Sakagami T. Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with Pneumocystis pneumonia.
ERJ Open Res. 2020 May 4;6(2):00306-2019.

Jodai T, Saruwatari K, Ikeda T, Moriyama E, Kashiwabara K, Shingu N, Iyonaga K, Inaba M, Ajishi Y, Honda C, Hirosako S, Maruyama H, Kakiuchi Y, Eida H, Tomita Y, Saeki S, Ichiyasu H, Sakagami T. Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.
Int J Clin Oncol. 2021 Jan;26(1):78-86.

Masunaga A, Takemura T, Ichiyasu H, Migiyama E, Horio Y, Saeki S, Hirosako S, Mori T, Suzuki M, Kohrogi H, Sakagamia T. Pathological and clinical relevance of selective recruitment of Langerhans cells in the respiratory bronchioles of smokers.
Respir Investig. 2021(in press).

Nakashima K, Saruwatari K, Sato R, Imamura K, Kajihara I, Fukushima S, Saito T, Ishizuka S, Tamanoi D, Jodai T, Hamada S, Tomita Y, Saeki S, Ichiyasu H, Oya N, Ihn H, Sakagami T. Non-small-cell Lung Cancer with Severe Skin Manifestations Related to Radiation Recall Dermatitis after Atezolizumab Treatment.
Intern Med. 2020 May 1;59(9):1199-1202.

Okabayashi H, Baba T, Ootoshi R, Shintani R, Tabata E, Ikeda S, Niwa T, Oda T, Okuda R, Sekine A, Kitamura H, Komatsu S, Hagiwara E, Takemura T, Sakagami T, Ogura T. Evaluation of lymphocytic infiltration in the bronchial glands of Sjögren’s syndrome in transbronchial lung cryobiopsy.
BMC Pulm Med. 2020 Oct 23;20(1):277.

Tenjin Y, Matsuura K, Kudoh S, Usuki S, Yamada T, Matsuo A, Sato Y, Saito H, Fujino K, Wakimoto J, Ichimura T, Kohrogi H, Sakagami T, Niwa H, Ito T. Distinct transcriptional programs of SOX2 in different types of small cell lung cancers.
Lab Invest. 2020 Dec;100(12):1575-1588.

Mito R, Matsubara E, Komohara Y, Shinchi Y, Sato K, Yoshii D, Ohnishi K, Fujiwara Y, Tomita Y, Ikeda K, Sakagami T, Suzuki M. Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation.
Pathol Int. 2020 May;70(5):287-294.

Tokunaga K, Kusunoki S, Hanazono Y, Mizumoto T. Malposition of femoral venous catheter into the hepatic vein.
J Emerg Crit Care Med. 2020;4:35.

Iwama E, Sakai K, Hidaka N, Inoue K, Fujii A, Nakagaki N, Ota K, Toyozawa R, Azuma K, Nakatomi K, Harada T, Hisasue J, Sakata S, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I. Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cancer 2020;126(1):219-227.

Ito K, Yamanaka T, Hayashi H, Hattori Y, Nishino K, Kobayashi H, Oya Y, Yokoyama T, Seto T, Azuma K, Fukui T, Kozuki T, Nakamura A, Tanaka K, Hirano K, Yokoi T, Daga H, Sakata S, Fujimoto D, Mori M, Maeno K, Aoki T, Tamura A, Miura S, Watanabe S, Akamatsu H, Hataji O, Suzuki K, Hontsu S, Azuma K, Bessho A, Kubo A, Okuno M, Nakagawa K, Yamamoto N. Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L) a multicenter retrospectice cohort study. Eur J Cancer. 2021; 145: 183-193.

Nithichanon A, Chetchotisakd P, Matsumura T, Takahashi Y, Ato M, Sakagami T, Lertmemongkolchai G. Diagnosis of NTM active infection in lymphadenopathy patients with anti-interferon-gamma auto-antibody using inhibitory ELISA vs. indirect ELISA.
Sci Rep. 2020 Jun 2;10(1):8968.

Yoshizawa K, Aoki A, Shima K, Tanabe Y, Koya T, Hasegawa T, Kikuchi T, Sakagami T. Serum Anti-interferon-γ Autoantibody Titer as a Potential Biomarker of Disseminated Non-tuberculous Mycobacterial Infection.
J Clin Immunol. 2020 Feb;40(2):399-405.

Tsuchiya T, Kamohara R, Muraoka M, Nagayasu T, Saeki S, Takenoyama M, Suzuki M, Inada K, Tokunaga S, Hayashi T, Urabe S, Koga T, Akamine S, Sugio K. A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
BMC Cancer. 2020 Dec;4(1):1192.

Kato R, Hayashi H, Chiba Y, Miyawaki E, Shimizu J, Ozaki T, Fujimoto D, Toyozawa R, Nakamura A, Kozuki T, Tanaka K, Teraoka S, Usui K, Nishino K, Hataji O, Ota K, Ebi N, Saeki S, Akazawa Y, Okuno M, Yamamoto N, Nakagawa K. Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
J Immunother Cancer. 2020 Feb:8(1):e000350.

Sakai K, Tsuboi M, Kenmotsu H, Yamanaka T, Takahashi T, Goto K, Daga H, Ohira T, Ueno T, Aoki T, Nakagawa K, Yamazaki K, Hosomi Y, Kawaguchi K, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Akamatsu H, Seto T, Saeki S, Sugio K, Nishio M, Okabe K, Yamamoto N, Nishio K. Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
Cancer Sci. 2021 Jan;112(1):388-396.